Precision Neuroscience Raises $250M for BCI Scale

Precision Neuroscience has closed an oversubscribed $250M Series D to expand the clinical, regulatory, manufacturing, and commercialization work around its Layer 7 brain-computer interface. Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed life-sciences investment fund co-led the financing announced September 24, 2026.

The round brings Precision's company-reported total capital to $430M. It arrives after more than 100 patient procedures across 18 medical institutions, FDA clearance for the Layer 7-T cortical electrode, a development partnership with Medtronic, and the buildout of a wholly owned MEMS manufacturing facility in Texas. The transaction is large because the remaining job is larger than decoding a neural signal: Precision must turn a high-resolution research interface into a repeatable medical product that hospitals, regulators, surgeons, and patients can trust.

What Precision Neuroscience announced

The $250M Series D was co-led by Pershing Square Inc., the Ackman Oxman Institute, and an unnamed life-sciences investment fund. Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital participated among others.

Precision said it will use the funding to expand its clinical program, move Layer 7 through additional FDA review, and build commercialization infrastructure. The company did not disclose a Series D valuation, investor check sizes, ownership changes, board terms, revenue, bookings, or a commercial-launch date. Precision's $430M total is a company-reported figure; public descriptions of the Series A, Series B, and Series C do not by themselves account for every dollar in that total.

The product sits on the brain's surface

Precision's Layer 7 Cortical Interface is a thin, flexible array designed to conform to the surface of the brain without penetrating brain tissue. Each module contains 1,024 electrodes, and Precision has demonstrated simultaneous recording across 4,096 electrodes. That density is intended to capture neural activity that software can translate into control of computers, phones, and robotic devices.

The distinction between the cleared component and the complete system is essential. FDA record K242618 covers the Layer 7-T cortical electrode for recording, monitoring, and stimulation of electrical activity on the brain's surface. Precision says the clearance supports implantation for up to 30 days, while its fully implantable wireless BCI remains in development and is not available for sale in the United States.

That regulatory boundary keeps the clinical evidence in proportion. Precision has published and supported peer-reviewed work on high-density surface recording, including research in Nature Biomedical Engineering, and has shown real-time decoding of intended movement. Those results support the platform's technical direction, but they are not the same as long-term therapeutic outcomes or approval for a permanent implant.

Clinical access is becoming an operating asset

Precision reports more than 100 patient procedures across 18 institutions, including programs with Penn Medicine, UChicago Medicine, Mount Sinai Health System, and West Virginia University's Rockefeller Neuroscience Institute. The scale gives the company access to diverse procedures, clinicians, brain regions, and research settings while it refines both the interface and the software interpreting neural activity.

The people behind those numbers matter. Research participants and clinical teams are producing the evidence a permanent implant pathway will need, and each additional site adds operational complexity alongside data. Protocol consistency, surgeon workflow, training, patient selection, follow-up, and data governance must improve with the network rather than fracture across it.

Manufacturing and hospital integration move into focus

Precision is carrying more of its manufacturing risk inside the company. Its Texas MEMS facility spans 22,000 square feet and includes a 5,500-square-foot ISO Class 5 clean room. Owning fabrication can tighten development loops and quality control, but it also makes Precision responsible for turning experimental hardware into a reproducible medical-device supply chain.

The Medtronic partnership addresses another part of the adoption problem. The companies are developing an integration between Layer 7 and Medtronic's StealthStation surgical-navigation platform, aiming to combine functional neural information with the anatomical view already used in operating rooms. That route could place Precision's technology inside an established neurosurgical workflow rather than asking hospitals to build a new one around an unfamiliar device.

The founding idea is now an institutional test

Precision was founded in 2021 around a surface-based approach to brain access. Its current leadership includes co-founder and CEO Michael Mager, co-founder and Chief Science Officer Benjamin Rapoport, and CTO Nate Pletcher. Precision also identifies Mark Hettick as a co-founder and VP of Engineering, while historical company and technical records place Demetrios Papageorgiou on the original founding team without assigning him a current operating role.

The Series D investor group reflects the breadth and time horizon of the next phase. Public-market capital, venture firms, sovereign capital, family offices, and a brain-focused institute are backing a program that must coordinate science, regulation, manufacturing, hospital relationships, and reimbursement before permanent BCI use can scale. The financing supplies time and capacity, but it does not settle the clinical or commercial questions.

What the $250M changes

The capital allows Precision to advance several dependencies in parallel. Clinical expansion can generate broader evidence, regulatory work can define the permanent-implant path, internal manufacturing can mature toward production, and commercial teams can prepare for how hospitals might evaluate, buy, support, and reimburse a new category of neurotechnology.

The next meaningful milestones will be specific: additional FDA decisions, evidence from longer-duration use, repeatable functional outcomes for intended users, production quality across larger volumes, and integrations that reduce the burden on clinical sites. Precision has financed the machinery around the interface. That machinery now has to make Layer 7 dependable beyond the research setting where its most visible achievements began.